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Abstract: Over the past 10 years the serological analysis of recombinant cDNA expression libraries (SEREX) has proved 
to be an effective method for the identification of tumour antigens. In the present study, two prostate cancer libraries were 
constructed and screened using autologous sera. Fifty five genes were isolated, including 46 known genes and 9 previ-
ously uncharacterised genes. Among the known genes, a metastasis-associated gene, MTA1, previously identified by dif-
ferential cDNA hybridisation, was preferentially expressed in a panel of malignant tissues compared with normal tissues, 
as analysed by reverse transcriptase-polymerase chain reaction (RT-PCR). MTA1 transcripts were observed to be over-
expressed in normal human testes as well as various cancer tissues when compared to the panel of normal tissues. MTA1 
antigen reacted with 2 of 13 allogeneic prostate cancer patient sera tested, but no sera reactivity was observed to any of the 
normal adult sera tested. Furthermore, a similar distribution and expression level of MTA-1 was observed in murine tis-
sues and cancer cell lines. Based on these findings and previous reports on the literature on this gene, MTA-1 can be con-
sidered not only as a “biomarker” of aggressive disease but also as a potential therapeutic target. 
Keywords: Tumour antigen, SEREX, EST and MTA1.  
INTRODUCTION 
  Identification of immunogenic cancer-associated proteins 
is a pre-requisite for the development of immunotherapy for 
cancer patients. The growing list of human tumour antigens 
recognised by cytotoxic T lymphocytes (CTLs) [1, 2] and 
antibodies [3, 4] provides convincing evidence of immune 
recognition by cancer patients and many are attractive targets 
for vaccine-based cancer therapies. Sahin and his colleagues 
developed a novel serological approach for the analysis   
of tumour antigens by recombinant expression cloning 
(SEREX), identifying human tumour antigens able to elicit a 
humoral immune response. This strategy is based on the con-
struction of cDNA expression libraries from tumour speci-
mens and immunoscreening the libraries with cancer pa-
tient’s serum, thus allowing a systematic search for im-
munoreactive proteins. SEREX has been applied to a wide 
range of tumour types, “novel” as well as previously defined 
tumour antigens have been identified using SEREX, includ-
ing MAGE-1 and tyrosinase, originally identified as tumour 
antigens recognised by CTLs [1, 2]. 
  To date, over 2700 antigens have been submitted to the 
SEREX database (http://ludwig-sun5.unil.ch/CancerImmun-
omeDB/SEREX_Intro.php). Although the majority of 
SEREX-defined genes have not been characterised beyond 
preliminary sequence analysis and determination of expres-  
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sion pattern, several have been proposed as attractive candi- 
dates for the construction of therapeutic cancer vaccines. For 
example, the cancer/testis antigen NY-ESO-1 was identified 
by screening an oesophageal cancer cDNA library and is 
regarded as one of most antigenic tumour antigens; antibody 
responses to NY-ESO-1 have been observed in 40-50% of 
patients with NY-ESO-1 expressing tumours and the pres-
ence of antibody strongly correlating with a CD8
+ T-cell 
response to the antigen [5]. Clinical trials, investigating the 
immunological and clinical response to vaccination with 
NY-ESO-1 peptides, especially in melanoma, are ongoing 
[6]. 
  In the present study we applied SEREX to identify pros-
tate cancer-associated antigens by screening cDNA expres-
sion libraries constructed from prostate cancer tissue. Fol-
lowing immunoscreening of two prostate cancer cDNA ex-
pression libraries with autologous serum, a panel of im-
muno-reactive antigens were identified. Included in this 
panel was metastasis-associated antigen1 (MTA1), a previ-
ously known antigen which we now report to be widely 
over-expressed in human and mouse tumours. Our results 
demonstrate that high levels of MTA1 transcripts are ex-
pressed in all murine tumour cell lines tested, compared with 
the low levels expressed in normal mouse tissues. MTA1 
expression has previously been correlated with more aggres-
sive tumours and may play a role in metastasis and invasion 
[7]. Moreover, because of its highly conserved sequence in 
humans and mice (96%), MTA1 may provide an ideal anti-
gen to be studied as a ‘self-antigen’ in mouse tumour models 
with significant relevance for human cancer immunotherapy.  
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MATERIALS AND METHODS 
Human Tissue Specimens, Tumour Cell Lines and Pa-
tient Sera 
  Tissue samples were obtained at the time of the surgery 
from the City hospital, Nottingham and Queen’s Medical 
Centre, Nottingham. All tumour tissue samples were verified 
histologically by observation of tissue sections by a clinical 
pathologist. Blood samples were obtained from patients and 
healthy male volunteers with no known evidence of benign 
or malignant prostatic disease and the serum collected was 
stored at -80°C. All patients gave informed consent and this 
study received local ethical approval. PC3 and DU-145 hu-
man prostate carcinoma cell lines were maintained
 in Dul-
becco's modified Eagle's medium supplemented with 10% 
heat
 inactivated foetal calf serum (FCS); the LNCaP human 
prostate carcinoma cell line was cultured in RPMI 1640 me-
dium with 10% FCS, 2mM L-glutamine, testosterone 
(5ng/ml) and hydrocortisone (5ng/ml). 
Murine Cell Lines and Tissues 
  CT26 (murine colon carcinoma) cells were maintained in 
DMEM media supplemented with 2mM L-glutamine and 
10% FCS; B16-F1 (murine melanoma) and CMT 93 (murine 
rectal carcinoma) cells, A20 (B cell lymphoma) cells and 
RENCA, a BALB/c renal carcinoma cell line were main-
tained by serial in vitro passage in RPMI 1640 tissue culture
 
medium supplemented with 2 mM L-glutamine, 10% FCS, 
and 0.05
 mM 2-ME.
 Normal mouse tissues were harvested 
from naïve Balb/c mice and were immediately snap frozen in 
liquid nitrogen and stored at -80˚ C. 
Construction of cDNA Expression Libraries 
  Two cDNA expression libraries were constructed from 
two tumour specimens of a well/moderately differentiated 
prostatic adenocarcinoma and an undifferentiated prostatic 
adenocarcinoma, respectively. These two specimens were 
obtained from Professor F Hamdy from patients attending 
Newcastle University under local ethical approval. Total 
RNA was isolated using RNA STAT-60 (ams Biotechnol-
ogy, UK) according to the manufacturer’s protocol. Poly(A)
+ 
RNA was purified from total RNA using a mRNA isolation 
kit (Stratagene UK) and cDNA was ligated into the ZAP 
Expression vector using Gigapack III Gold cloning kit 
(Stratagene UK). After in vitro packaging, two libraries con-
taining 1.210
6 and 2.010
6 primary cDNA clones respec-
tively were obtained.  
Immunoscreening of the cDNA Library 
  Immunoscreening of the cDNA library was performed as 
described by Sahin et al. [3]. Briefly, 1:10 diluted autologous 
patient’s serum and allogeneic sera, were preabsorbed with 
E.coli-phage lysate to remove antibodies reactive with anti-
gens related to the vector system. In order to eliminate 
cDNA clones encoding human immunoglobulins, mem-
branes were pre-screened with AP-conjugated rabbit anti-
human IgG, Fc fragment specific secondary antibody 
(Pierce, USA) prior to incubation with sera. Reactive plaques 
were detected with 5-bromo-4-chloro-3-indolyl-phosphate/ 
nitroblue tetrazolium (BCIP/NBT), marked and excluded 
from further study. The membranes were then incubated 
with pre-absorbed 1:200 diluted patient’s serum and serum-
reactive clones were detected with AP-conjugated secondary 
antibody and visualized by incubating with BCIP/NBT. The 
reactive phage clones were subcloned to monoclonality and 
converted to pBK-CMV phagemids. To assess frequencies of 
antibody responses to the SEREX defined antigens in indi-
vidual allogeneic sera from prostate cancer patients and 
normal individuals, E. coli were transfected with approxi-
mately equal numbers of positive phage and non-
recombinant phage. These were then screened with 1:200 
diluted individual allogeneic serum samples as described 
above, excluding the IgG pre-screening step. 
DNA Sequencing and Sequence Analysis 
  Phagemid DNA was purified using QIAprep Spin Mini-
prep kit (QIAGEN,  West Sussex, UK), analysed by 
EcoRI/XhoI restriction enzyme digestion and clones repre-
senting different cDNA inserts were sequenced using an ABI 
PRISM 310 automatic sequencer (Applied Biosystems UK). 
Sequence alignments were performed using the GenBank 
database (www.ncbi.nlm.nih.gov). Genes identical with en-
tries in the GenBank were classified as known genes, 
whereas those that shared sequence similarity only with 
ESTs and those that had no similarity to entries in either the 
GenBank or EST databases were classified as unknown 
genes. Multiple sequence alignments were performed with 
DNASIS (Hitachi Software Engineering Co Ltd) and MA-
CAW (NCBI) software. Chromosomal localisation and 
exon-intron organisation for uncharacterised cDNAs was 
determined by comparison to the working draft of the human 
genome.  
Conventional Reverse Transcription PCR (RT-PCR) 
Analysis 
  To evaluate the mRNA distribution of SEREX-defined 
antigens, total RNA from a panel of normal human tissues 
(lung, liver, brain, trachea, heart, and kidney) was purchased 
from Clontech, (UK). Total RNA from normal testes, oeso-
phageal cancer and adjacent non-tumour tissues, head and 
neck tumour and adjacent non-tumour tissues, prostate can-
cer tissues, stomach cancer and kidney cancer tissues and 
cell lines (DU-145, LNCaP and PC3) was isolated using 
RNA STAT-60 reagent (ams Biotechnology, UK) according 
to the manufacturer’s protocol. For mouse tissue screening, 
several tissues were dissected from mice and immediately 
snap frozen. Tissues were then ground in liquid nitrogen 
before proceeding to total RNA isolation using RNA STAT-
60. The first-strand cDNA was synthesised from 2μg of total 
RNA primed with oligo-dT(15) (Promega UK) as described 
in the manufacturer’s protocol. Human MTA1 (5’-
CGCTCAAGTCCTACCTGGAG and 3’-TGGTACCGGT 
TTCCTACTCG) and GAPDH (5’-ACCACCAACTGCTTA 
GCACC and 3’-CCATCCACAGTCTTCTGGGT) specific 
primers were used to verify expression of hMTA1. The 
mouse MTA1 gene specific primers (5’-GCGAGAGCTGT 
TACACCACA and 3’-ACTGCTGAGCACACTGGATG) 
and murine GAPDH primers (5’-GGTGAAGGTCGGAGT 
CAACGGA and 3’-GAGGGATCTCGCTCCTGGAAGA) 
were designed with the assistance of the Primer3 website and 
obtained lyophilized from Sigma Genosys (UK). The gene 
specific PCR primers were designed to ensure that the 
primer sequences were located within different exons and 
that the PCR products obtained were 300-500bp in length. 102    The Open Biochemistry Journal, 2008, Volume 2  Li
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GAPDH was used as an internal control to observe the rela-
tive amounts of cDNA from each sample that was used in 
the RT-PCR reaction. The cDNA templates were used in the 
PCR in a final volume of 50 l containing 0.4 μM of each 
primer, 1.5  mM MgCl2, 0.2  mM deoxynucleotide triphos-
phates (dNTPs) and 2.5 U Taq polymerase (Promega, UK).  
  PCR conditions were as follows for MTA1: Initial de-
naturation at 95ºC for 5 mins, followed by 34 cycles of de-
naturation at 95ºC for 1 min, annealing at 58ºC for 1 min and 
extension at 72°C for 1 min. This was followed by a final 
extension step at 72°C for 5 mins. GAPDH PCR conditions 
consisted of 25 cycles of denaturation at 94ºC for 45 secs, 
annealing at 58ºC for 45 secs and extension at 72°C for 45 
secs. Semi-quantitative analysis of RT-PCR products was 
performed by 1.5  %  (w/v) agarose gel electrophoresis and 
ethidium bromide visualization. After normalization to 
GAPDH mRNA as a control for each cDNA template, the 
expression of gene-specific mRNA in the cDNA samples 
tested was compared. 
RESULTS 
Identification and Characterisation of Immunoreactive 
cDNA Expression Clones 
  After immunoscreening of 8 x 10
5 pfu from each of two 
prostate carcinoma cDNA expression libraries with the 
autologous serum, a total of 26 and 73 immunoreactive 
clones were identified from first and second cDNA expres-
sion libraries, respectively. These clones were purified, in 
vivo  excised, and converted to pBK-CMV plasmid forms. 
The cDNA inserts were analysed using restriction mapping 
and sequencing. Sequence comparison against GenBank and 
EST databases showed that these clones were derived from 
54 distinct genes, which were designated as Pr1-Pr54. Pr1-
Pr11 were derived from the first cDNA library and the re-
maining clones from the second library. Eight genes showed 
no sequence similarity or only partial sequence similarity 
with genes in the GenBank database but shared sequence 
similarity with ESTs derived from various tissues (referred 
to as “unknown genes”) (Table 1).  
  We therefore investigated these genes further and EST 
analysis of Pr3 (BC017874), Pr9 (BC062419), Pr10 
(XM_496394), Pr11 (AC011375), Pr43 (NM_014929) and 
Pr50 (BC007379), showed that they shared sequence identity 
with reported ESTs derived from various normal tissues, e.g. 
lung, liver, kidney, brain and B cells, suggesting that these 
genes are widely expressed in human tissues (Table 1). Pr6 
(AC104841) transcripts on the other hand looked more 
promising as no similarities with normal tissue were found 
which was confirmed in a panel of RNAs isolated from nor-
mal human tissues as determined by RT-PCR after 40 cycles 
of amplification. Unfortunately we were also unable to de-
tect it in a panel of tumour tissues or tumour cell lines. The 
last one, Pr52, is located on chromosome 7p21 and is similar 
only to an EST derived from human placenta (DA832074). 
The tissue expression pattern of this gene was therefore 
evaluated by RT-PCR and results showed that Pr52 was ex-
pressed in normal brain, kidney, thyroid, testis and placenta 
(data not shown). It was however not found at the time of 
this investigation whether the expression of these genes was 
higher in cancer tissues compared to normal tissue. Further 
work is now being carried out to evaluate this using real-time 
RT-PCR. 
  The remaining 46 genes showed sequences identical with 
or highly similar to known GenBank entries (“known 
genes”) (Table 2). Three of these had been previously iso-
lated from other tumour tissues by SEREX (Pr 17, 48 and 
54). Clone Pr54 is identical to human transcriptional coacti-
vator tubedown-100 (TBDN100), which is involved in regu-
lation of angiogenesis and was isolated by us from gastric 
cancer and is overexpressed in gastric cancer tissues com-
pared with adjacent non-cancer tissues (Ga19, GenBank ac-
cession number AY039242) [4]. Clone Pr48 is similar to the 
gene encoding human ankyrin repeat domain 17, which has 
also been isolated from breast cancer (NY-BR-16, Genbank 
accession number AF308285) [8]. Clone Pr17 is identical to 
human NEDD8 ultimate buster-1 (NUB1) mRNA, which 
was detected in renal cell carcinoma (NY-REN-18, Genbank 
accession number AF155099) [9].  
Immune Recognition of the SEREX-Defined Antigens by 
Serum Antibodies from Prostate Cancer Patients and 
Normal Individuals 
  To determine whether immune recognition of antigens 
encoded by SEREX genes was tumour-related, allogeneic 
sera from normal individuals and patients with prostate can-
Table 1.  Novel Proteins Identified by SEREX Analysis of Prostate Cancer cDNA Expression Libraries with Autologous Sera  
Designation  No of Clones  GeneBank Acc. nos  Descriptive feature 
Pr3   2  BC017874   Hypothetical protein MGC40405. EST: lung, stomach, ovary, brain etc. 
Pr6   3  AC104841   BAC clone RP11-475G3 
Pr9   1  BC062419   Family with sequence similarity 36. EST: Lung, liver, skin, kidney etc. 
Pr10  1  XM_496394  Similar to KIAA1693 protein. EST: Brain, liver, spleen, stomach, heart etc. 
Pr11  1  AC011375   EST: Foetal pancreas, embryonic stem cells, pooled tumours etc. 
Pr43  1  NM_014929  KIAA0971 protein. EST: liver, kidney, stomach, placenta, testis etc. 
Pr50  1  BC007379   Hypothetical protein MGC16207. EST: carcinoma, neuroblastoma, lung, colon etc. 
Pr52 1  AC004982    PAC clone RP5-1159O4 from 7p21-p22. EST: only similar to an EST derived from the 
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Table 2.  Known Proteins Identified by SEREX Analysis of Prostate Cancer cDNA Expression Libraries Screened with Autologous 
Sera 
Designation  No of Clones  GeneBank Acc. nos  Identity 
Pr1   3   NM_002078    Trans-Golgi P230 
Pr2   2   BC027473    aarF domain containing kinase 4  
Pr4   1   NM_015265    SATB family member 2 
Pr5   6  AY495330    Mitochondrial protein 
Pr7   3   NM_001012    Ribosomal protein S8 
Pr8   1   NM_000990    Ribosomal protein L27a 
Pr12   6   M91083    DNA-binding protein (HRC1) 
Pr13   1   M91083    A new spliced isoform of HRC1 
Pr14   7   NM_015895    A new spliced isoform of geminin, DNA replication inhibitor 
Pr15   1   NM_013232    Programmed cell death 6.  
Pr16   1   NM_004689    Metastasis associated 1 
Pr17   5   AF155099    NY-REN-18 antigen ; NUB1 
Pr18   1   NM_006753    Surfeit 6 
Pr19   1   M34667    Phospholipase C-gamma 
Pr20   1   NM_004501    Scaffold attachment factor A 
Pr21   1   NM_003367    Upstream transcription factor 2 
Pr22   1   NM_005154    Ubiquitin specific protease 8 
Pr23   2   BC006398    Vesicle docking protein p115 
Pr24   3   NM_002792    Proteasome (PSMA7) 
Pr25   1   NM_203380    Acyl-CoA synthetase long-chain family member 5 (ACSL5) 
Pr26   1   NM_006356    ATP synthase 
Pr27   2   BC058921    Glutamyl-prolyl-tRNA synthetase 
Pr28   1   NM_006013    Ribosomal protein L10 
Pr29   1   BC020515    Ribosomal protein S14 
Pr30   1   NM_000980    Ribosomal protein L18a 
Pr31   1   NM_001014  Ribosomal protein S10 
Pr32   1   NM_000994  Ribosomal protein L32 
Pr33   1   BC000443   Tumor protein p53 inducible protein 11. 
Pr34   4   BC037545   Poly (ADP-ribose) polymerase family, member 1 
Pr35   1   NM_003747  Tankyrase 
Pr36   1   HSA010840  ATP-dependent RNA helicase  
Pr37   1   NM_006201  PCTAIRE protein kinase 1  
Pr38   1   NM_001694  ATPase, H+ transporting 
Pr39   1   NM_005627  Serum/glucocorticoid regulated kinase  
Pr40   3   NM_002032  Ferritin, heavy polypeptide 1 
Pr41   1   NM_015965  Cell death-regulatory protein GRIM19 
Pr42   1   BC019315   N-acetylneuraminic acid synthase  
Pr44   6   AF413079   Centaurin gamma3  
Pr45   2   AF438201   Tankyrase II  
Pr46   1   BC070234   Ankyrin repeat domain 12  
Pr47   1   NM_012111  AHA1, activator of heat shock 90kDa protein ATPase homolog 1 
Pr48   2   AF308285   NY-BR-16; ankyrin repeat domain 17  
Pr49   1   NM_016505  Putative S1 RNA binding domain protein 
Pr51   1   NM_173593  Beta 1,4-N- acetylgalactosaminyltransferase- transferase-III 
Pr53   1   NM_133636  DNA helicase HEL308  
Pr54   1   AY039242   Gastric cancer antigen Ga19 
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cer were tested for antibody reactivity against selected anti-
gens using a protein array system. Of the 35 antigens 
screened, 17 antigens reacted with a subset of sera from both 
normal individuals and cancer patients; thus, approximately 
half (17/35) of the antigens identified in this study were non-
cancer related and were classified as naturally occurring 
autoantigens. Nine proteins had a cancer-related serological 
profile, reacting only or mainly with sera from prostate can-
cer patients. The remaining antigens only reacted with 
autologous serum and not with any allogeneic sera from 
normal individuals or patients with prostate cancer (Table 3). 
  From the panel of genes identified, we decided to focus 
on genes which did not generate any reactivity to serum ob-
tained from normal patients, since these are more likely to 
demonstrate cancer-specific immunological responses. These 
genes included the aarF domain containing kinase 4 
(ADCK4), for which very little information could be found; 
the ribosomal protein S10, which has previously been shown 
to be deregulated in colorectal cancer samples, along with 
larger transcripts being produced in addition [10]; the cell 
death regulatory protein GRIM19, which appears to be an 
important cell death regulatory protein and is involved in 
Table 3.  Reactivity of SEREX-Defined Antigens Screened with Sera from Healthy Donors and Patients with Prostate Cancer 
Serological reactivity  Designation Identity 
Control Pca 
Pr1 
Pr2 
Pr3 
Pr4 
Pr5 
Pr6 
Pr7 
Pr8 
Pr9 
Pr10 
Pr11 
Pr12 
Pr13 
Pr14 
Pr15 
Pr16 
Pr17 
Pr18 
Pr19 
Pr20 
Pr21 
Pr22 
Pr23 
Pr24 
Pr25 
Pr26 
Pr27 
Pr28 
Pr29 
Pr30 
Pr31 
Pr32 
Pr35 
Pr41 
Pr52 
Trans-Golgi P230 autoantigen 
aarF domain containing kinase 4 
Unknown 
SATB2 
Mitochondrical protein 
Unknown 
Ribosomal protein S8 
Ribosomal protein L27a 
Hypothetical protein LOC116228 
Similar to AB25 
Unknown 
DNA-binding protein (HRC1) 
A alternatively spliced isoform of HRC1 
Geminin, DNA replication inhibitor 
Calcium binding protein (ALG-2) 
Metastasis-associated1 (MTA1) mRNA 
NEDD8 ultimate buster-1 
Surfeit 6 
Phospholipase C-gamma mRNA 
Scaffold attachment factor A 
Upstream transcription factor 2, c-fos interacting 
Ubiquitin specific protease 8  
Vesicle docking protein p115 
Proteasome subunit HSPC  
fatty-acid-Coenzyme A ligase, long-chain 5  
F1F0-type ATP synthase subunit d mRNA 
glutamyl-prolyl-tRNA synthetase 
Ribosimal protein L10 
Ribosomal protein S14 
Ribosomal protein L18a 
Ribosomal protein S10 
Ribosomal protein L32 
Tankyrase 
Cell death-regulatory protein GRIM19 
Unknown 
5/5  
 0/14 
 2/14 
 1/14 
 0/4  
 3/13 
 6/13 
 0/13 
 1/10 
 2/13 
 0/7  
 0/13 
 0/13 
 1/13 
 1/17 
 0/13 
 1/17 
 4/13 
 0/13 
 0/13 
 0/13 
 3/17 
 0/13 
 6/17 
 4/17 
 0/13 
 5/17 
 2/6  
 2/5  
 3/5  
 0/4  
 0/4  
 2/4  
 0/6  
 2/11 
9/9  
 4/13 
 6/7 
 2/13 
 0/9 
 12/14 
 13/14 
 1/14 
 1/7 
 6/14 
 0/6 
 0/8 
 1/8 
 1/8 
 4/13 
 2/13 
 1/13 
 3/8 
 0/8 
 0/8 
 0/8 
 7/13 
 0/8 
 10/13 
 8/13 
 0/8 
 10/13 
 5/10 
 5/10 
 4/10 
 5/10 
 0/10 
 4/10 
 5/12 
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mitochondrial metabolism. Loss of GRIM-19 expression has 
been shown to be associated with renal cell carcinomas. In-
terestingly, GRIM-19 mutations have been observed in mito-
chondrial rich tumours of thyroid [11]. Considering that it is 
one of the critical regulatory proteins and its expression is 
responsible for tumour cell death, it seems an unlikely anti-
gen for immunotherapy. And finally, MTA1 which was 
found to represent the most promising gene based on previ-
ously published literature reporting on its overexpression in 
various cancers. Moreover, being highly expressed in metas-
tatic cells suggests that it would be a highly specific thera-
peutic target which could be potentially used to prevent dis-
ease relapse in advanced disease states. Also, several studies 
have clearly established that MTA1 overexpression leads to 
cell transformation and by suppressing MTA1 expression 
you get an inhibition of cell growth [12,13]. 
  The expression pattern of MTA1 transcripts in a panel of 
normal human tissues, matched human non-tumour and tu-
mour tissues, human prostate cancer tissues and cell lines 
was analysed by RT-PCR. Weak expression of MTA1 tran-
script was detected in normal human tissues except testis, 
where MTA1 was highly expressed (Fig. 1A). Human head 
and neck tumours and oesophageal cancer tissues expressed 
higher levels of MTA1 transcripts than matched non-tumour 
tissues (data not shown). MTA1 mRNA is highly expressed 
in human prostate cancer cell lines and a significant number 
of prostate, renal and stomach cancer tissues (Fig. 1B). We 
further analysed the expression of MTA1 in murine tissues 
and tumour cell lines since MTA1 is highly conserved in 
humans and mouse demonstrating 96% similarity at the pro-
tein level. MTA1 was found to be over-expressed in all mur-
ine tumour cell lines as compared to normal tissues, except 
the testis (Fig. 1C), which showed a similar level of expres-
sion to tumour tissues (data not shown). In comparison, all 
the normal tissues examined expressed MTA1 at very low 
levels (Fig. 1C). Interestingly, we found that MTA1 was 
expressed at low levels in muscle tissue compared to other 
tissues, which contradict previously published work where 
no MTA1 expression was found [14]. 
DISCUSSION 
  A number of autoimmunogenic tumour antigens have 
been identified by screening with autologous CTL. However, 
the methodology for defining T cell-recognised tumour anti-
gens is dependant on generating T cell clones and establish-
ing tumour cell lines; conditions that are frequently difficult 
to meet and virtually impossible in the case of certain tumour 
types, such as prostate cancer. In the present study, using a 
serological technique termed SEREX, we have identified 54 
different antigens by immunoscreening two cDNA expres-
sion libraries constructed from two different prostate cancer 
tissues using autologous serum. Eight antigens were encoded 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (A) Expression of MTA1 in normal human tissues analysed by RT-PCR. Cycling conditions were optimized so that the RT-PCR 
products were analyzed when amplification is within the linear phase. Lanes 1-9 from left to right, normal brain, kidney, heart, liver, lung, 
PBMC, testis, negative control and DNA ladder. (B) Tissue distribution of MTA1 transcript in malignant tissues and cell lines was analysed 
by RT-PCR. Lanes 1-4: prostate cancer tissues; lanes 5-7: prostate cancer cell lines (lane 5: DU-145; lane 6: LNCaP; lane 7: PC3); lanes 8-
11: renal cancer; lanes 12-16: gastric cancer. Amplification of GAPDH was also performed in parallel as a control in all samples. (C) Aga-
rose gel electrophoresis of mGAPDH and mMTA1 following RT- PCR from murine tumour cell lines and tissues. Lanes 1-10 from left to 
right, CT26, A20, RENCA, CMT, B16, liver, lung, muscle, spleen, kidney. 
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by unknown genes and the remaining 46 were identified 
from database screening, three having been previously de-
tected by SEREX analysis in other tumour types – Pr17 in 
renal cell carcinoma, Pr48 in breast cancer and Pr54 in gas-
tric cancer. Our data has further demonstrated that SEREX is 
an efficient technique for the identification of tumour anti-
gens that elicit humoral immune response in cancer patients. 
  To determine which of our panel of antigens showed a 
tumour-restricted immunogenicity, we analysed the fre-
quency of the antibody responses using sera from cancer 
patients as well as healthy individuals. Nine antigens reacted 
with sera from allogeneic prostate cancer patients (in addi-
tion to autologous serum reactivity), indicating that the im-
mune response to these antigens is cancer-associated. Three 
of these antigens are encoded by unknown genes (Pr3, Pr6 
and Pr Pr52 respectively); additionally three of them (Pr8-
ribosomal protein L27a, Pr16-MTA1 and Pr31-ribosomal 
protein S10) have previously been reported to be over-
expressed in cancer [10, 15]. Screening, using a larger panel 
of sera from patients with other cancers is required to estab-
lish the cancer specific immunogenicity of these antigens. 
  This study has identified a number of immunogenic 
self-proteins demonstrating sera-reactivity with both normal 
and prostate cancer patients sera. A possible reason for the 
immunogenicity of self-proteins are structural changes re-
sulting from mutations, translocations or splice variants. We 
have identified previously unknown splice variants of two 
genes, geminin, a DNA replication inhibitor represented by 
clone Pr14, and HRC1, a DNA-binding protein represented 
by clone Pr13 (unpublished data). Alterations in the pattern 
and efficiency of alternative splicing of several pre-mRNAs 
(e.g. CD44, BRCA1, WT-1) have been implicated in tu-
mourigenesis and correlated with tumour progression [16, 
17]. De-regulation of splice site selection may serve as an 
additional mechanism for the generation of protein diversity 
contributing to the selection of more aggressive tumour cells 
[18, 19]. Interestingly, alternate splice variants for the mur-
ine MTA1 gene have recently been discovered in various 
mouse tissues and these variants were differentially localised 
within the cell [20]. However, their functional significance is 
not yet known and it would be of interest to determine 
whether human tissues express similar splice variants.  
  Several SEREX antigens identified in this study have 
been previously reported to be upregulated in different types 
of cancer; HRC1 (Pr12) was reported to be overexpressed in 
the bladder carcinoma cell line [21]; programmed cell death 
6 (Pr15) was found to be directly involved in apoptosis and 
was upregulated in rat liver hepatoma and human lung can-
cer [22]; MTA1 (Pr16) was originally identified by differen-
tial cDNA hybridisation using RNA from metastatic and 
non-metastatic rat mammary adenocarcinoma cell lines [23]; 
human MTA1 was initially cloned by homology searching to 
rat MTA1 [24] and is a component of the histone deacetylase 
and nucleosome-remodelling complexes.  
  In the current study, MTA1 has been shown for the first 
time, to elicit a humoral immune response in prostate cancer 
patients. The expression pattern of MTA1 in normal and 
tumour tissues was analysed by RT-PCR and the data ex-
tends previously published findings, where MTA1 was 
shown to be over-expressed in prostate cancer cell lines, 
prostate cancer, renal cancer, gastric cancer, oesophageal 
cancer, and head and neck tumour tissues but only weakly 
expressed in normal tissues except the testis. We also ana-
lysed the expression pattern of the murine MTA1 gene in 
different tissues and in tumour cell lines. Most of the tissues 
expressed MTA1 transcripts at low levels, whereas high lev-
els of expression were observed in all tumour cell lines. 
These results have been confirmed by real time RT-PCR and 
western blotting (unpublished results). Several peptides, 
MHC class-I and class-II, derived from MTA1 were identi-
fied using the online-based algorithm “SYFPEITHI” and 
synthesised. Using our transgenic mouse model, many of 
them were able to induce the generation of cytotoxic T lym-
phocytes that were capable of killing peptide-pulsed target 
cells but none of them could kill tumour cells naturally over-
expressing MTA1 suggesting that these peptides were not 
endogenously processed. These were also confirmed after 
immunisation with cDNA encoding for the whole of MTA1 
gene (data not shown). 
  In conclusion, we screened two prostate cancer libraries 
using autologous sera and isolated 54 genes, including 46 
known genes and 8 previously uncharacterised genes. 
Among these, we identified MTA1 and our data extends pre-
viously published studies regarding its over-expression in 
aggressive tumours. MTA1 has previously been found to be 
associated
 with progression to the metastatic state in various 
cancers and our observations suggest that MTA1 may be a 
useful target for immunotherapy of cancer in the advanced 
and metastatic stages of disease progression even though we 
have so far failed to find naturally endogenously processed 
MTA1 derived peptides. It is also possible that strong im-
mune tolerance exists towards such ubiquitously expressed 
proteins and therefore a stronger means of immunisation 
would be required in order to break tolerance. 
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